-
Olmotevirumab injection is approved for marketing, adding a new option for passive immunization against rabies virus
Time of Update: 2022-05-03
Recently, a recombinant human anti-rabies virus monoclonal antibody injection for the prevention of rabies, omitevirumab injection (English name: Ormutivimab Injection; trade name: Xunke), was approved by the National Medical Products Administration of China (NMPA).
-
Han Yuewei, director of China Resources Shuanghe, resigns
Time of Update: 2022-05-03
On February 14, China Resources Shuanghe announced that due to work arrangements, Han Yuewei applied for his resignation as a director and member of the special committee of the ninth board of directors of the company .
-
FDA issues draft regulatory guidance for antibody conjugated drugs, these points deserve attention
Time of Update: 2022-05-03
When developing ADC molecules, in vitro drug interaction analysis needs to be incorporated to understand the potential risks of unconjugated payloads and active metabolites .
-
Yifan Pharmaceutical's application for registration and marketing authorization for phenylephrine hydrochloride injection was accepted
Time of Update: 2022-05-03
received the domestic registration and listing of phenylephrine hydrochloride injection issued by the State Food and Drug Administration on February 16, 2022.
is listed on the market for phenylephrine injection.
-
Introduced by Hutchison Medicine!
Time of Update: 2022-05-03
TextPharmaceutical GuanlanAccording to the China Drug Clinical Trial Registration and Information Publicity Platform, Epizyme has launched an international multi-center (including China) Phase 3 clinical trial of tazemetostat in the treatment of relapsed/refractory follicular lymphoma .
-
To regain the top 1 of global pharmaceuticals?
Time of Update: 2022-05-03
In addition, Pfizer publicly predicted that sales in 2022 will increase to $102 billion, a record!Compared with the first three quarters, Pfizer changed its financial report structure in the fourth quarter of 2021, and classified the six general categories of vaccines, oncology, internal medicine, hospitals, inflammation and immunity, and rare diseases as Pfizer Biopharma (BioPharma).
-
Sinopharm Modern Cefixime Capsules and Cefaclor Dry Suspension Passed the Consistency Evaluation of Generic Drugs
Time of Update: 2022-05-03
Up to now, Sinopharm Zhijun has invested approximately RMB 27 million in R&D (unaudited) for the consistency evaluation of cefixime capsules (0.
Up to now, Sinopharm Zhijun has invested approximately RMB 22 million (unaudited) in research and development for the consistency evaluation of cefaclor dry suspension (0.
-
Zejing Pharmaceutical's KRAS G12C Inhibitor Launches Clinical Trials in China
Time of Update: 2022-05-03
According to the China Drug Clinical Trial Registration and Information Publicity Platform, Zejing Bio has initiated a Phase 1/2 clinical study of ZG19018 in the treatment of patients with advanced solid tumors with KRAS G12C mutation .
-
China Antibody Pharmaceutical's IND application for anti-IL-17RB antibody accepted by FDA
Time of Update: 2022-05-03
(hereinafter referred to as "China Antibody Pharmaceuticals") announced that the company has submitted a new drug clinical trial application (IND) for the anti-IL-17RB monoclonal antibody SM17 to the US FDA, and has It has been accepted by the FDA and is intended to be developed for the treatment of asthma .
-
The Shenzhen Medical Insurance Bureau arrested 17 people involved in the case and reported AstraZeneca's insurance fraud incident
Time of Update: 2022-05-03
In August 2021, AstraZeneca found in an internal compliance inspection that a small number of employees in Shenzhen had tampered with or participated in tampering with patient test reports, suspected of defrauding medical insurance funds .
-
FDA grants Bayer's oral FXIa inhibitor asundexian Fast Track designation!
Time of Update: 2022-05-03
asundexian is an oral factor XIa (FXIa) inhibitor currently being developed as a potential drug for secondary prevention in patients with NCIS, as well as 2 other diseases: atrial fibrillation (irregular heartbeat) and recent myocardial infarction (heart attack) .
-
Zai Lab's ROS1/NTRK targeted inhibitor included in breakthrough therapy
Time of Update: 2022-05-03
According to an earlier Zai Lab press release, the Phase 2 registrational portion of the TRIDENT-1 study is a multicenter study evaluating repotrectinib in patients with ROS1-positive advanced NSCLC and in patients with NTRK-positive advanced solid tumors .
-
The negative controversy of the JAK inhibitor continues, and its Opzelura is still a great success after the launch
Time of Update: 2022-05-03
Incyte Chief Executive Herve Hoppenot said Tuesday that the launch of Opzelura has been "extremely successful" so far, with the topical cream reaching nearly 19,000 patients in the fourth quarter after its official launch in mid-October, with 500 sales.
-
349 medicines will be transferred out of medical insurance
Time of Update: 2022-05-02
com, excluding the varieties that have been included in the national medical insurance, there are 41 varieties supplemented by 15 or more provinces and cities (12 of which are 20 or more), of which 35 are chemical drugs and 6 are Chinese patent medicines.
-
Sanjitang glimepiride was disqualified from being selected as a substitute for Conquer Pharmaceuticals
Time of Update: 2022-05-02
On February 23, Shanghai Sunshine Pharmaceutical Purchasing Network issued an announcement saying that the glimepiride tablets produced by Shengjitang had been disqualified from the second batch of national procurement due to non-compliance with the quality management standards for drug production.
-
66 varieties cancel the medical insurance code, 37 varieties suspend online purchases
Time of Update: 2022-05-02
Strict risk control, high quality and high price Structural adjustment of Chinese herbal decoction pieces According to the 2021 version of the medical insurance drug catalog, a total of 892 kinds of Chinese herbal medicines can be paid by the medical insurance fund .
-
The development of AI pharmaceuticals continues to accelerate, and the pharmaceutical equipment industry may usher in a major upgrade
Time of Update: 2022-05-02
In addition to Fosun Pharma, Pfizer announced in mid-January that it would expand its existing strategic cooperation with PostEra to establish an artificial intelligence laboratory (AI Lab) to jointly promote the development of new drugs .
-
In 2022, there will be many good news in the field of double-antibody drugs, and the market will explode
Time of Update: 2022-05-02
On January 5, Pharmaco announced that its self-developed Kadeninumab (AK104) combined with AK112 double antibody phase Ib/II clinical trial application was approved by NMPA, with or without chemotherapy for the treatment of advanced non-small cell lung cancer.
-
Within 1 day, the executives of China Resources Sanjiu and other two pharmaceutical companies changed
Time of Update: 2022-05-02
According to the report, Li Weijun applied to resign as the company's director, vice president and member of the compensation and appraisal committee of the board of directors due to personal reasons, and at the same time resigned from all positions held in the company's subsidiaries .
-
The transformation of the pharmacy industry is accelerating, and the development of diversification and specialization has become the general trend
Time of Update: 2022-05-02
Enterprises have been determined to carry out the pilot work of comprehensive reform of large chain convenience stores operating only Class B non-prescription drugs in the whole province .
As early as 2020, it issued an announcement stating that the company and its wholly-owned subsidiary Hainan Hongxiang Yixintang Pharmaceutical Chain Co.
